Fractyl Health (NASDAQ: GUTS) is advancing two one-time treatment approaches targeting obesity, type 2 diabetes, and related metabolic diseases, with CEO Harith Rajagopalan highlighting the goal of durable benefits during a Canaccord discussion.
Fractyl Health (NASDAQ: GUTS) is advancing two one-time treatment approaches targeting obesity, type 2 diabetes, and related metabolic diseases, with CEO Harith Rajagopalan highlighting the goal of durable benefits during a Canaccord discussion.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.10
Ticker Sentiment
